Those tracked by the Wall Street Journal have BNGO rated as a consensus « buy » with an average $12 price target.
Similarly, Will BNGO get FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Is BNGO a pump and dump? BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
Thereof, What are analyst saying about BNGO stock?
Stock Price Forecast
The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +234.03% increase from the last price of 2.40.
Is BNGO a strong buy?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Bionano Genomics stock is Buy based on the current 3 buy ratings for BNGO.
Does Ark hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.94, with a high estimate of 86.57 and a low estimate of 24.08. The median estimate represents a +67.62% increase from the last price of 19.65.
What does BNGO company do?
Company Description
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
What ETFS have BNGO?
(BNGO) exposure | ETF.com.
…
ETFs with the most BNGO shares.
| Ticker | Fund Name | # OF SHARES |
|---|---|---|
| IWO | iShares Russell 2000 Growth ETF | 2.31M |
| KOMP | SPDR S&P Kensho New Economies Composite ETF | 1.80M |
| VTI | Vanguard Total Stock Market ETF | 1.72M |
| SCHA | Schwab U.S. Small-Cap ETF | 1.17M |
Does Vanguard hold BNGO?
Institutional investors purchased a net $3.1 million shares of BNGO during the quarter ended March 2019.
…
Top 10 Mutual Funds Holding Bionano Genomics Inc.
| Mutual fund | Vanguard Russell 2000 Index Fund |
|---|---|
| Shares owned | 788,843 |
| Total value ($) | 1,688,124 |
| Shares bought / sold | +33,379 |
| Total change | +4.42% |
Is BNGO in ETF?
Bionano Genomics is a life sciences instrumentation company in the genome analysis space.
…
| ETF | BNGO |
|---|---|
| Shares Out. | 289.18M |
| Market Cap. | 615.96M |
| Div/Shr | 0.00 |
| Div Yield | 0.00 |
Is BNGO an American company?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. … The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
What sector is BNGO in?
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.
What institutions are buying NIO?
Largest shareholders include Baillie Gifford & Co, BlackRock Inc., Vanguard Group Inc, State Street Corp, VWIGX – Vanguard International Growth Fund Investor Shares, Susquehanna International Group, Llp, Goldman Sachs Group Inc, Citadel Advisors Llc, VEIEX – Vanguard Emerging Markets Stock Index Fund Investor Shares, …
Is it good to invest in Nio?
Investing in Nio today is best suited for investors willing to face extreme volatility and very high risk. However, the old saying that the greater the risk, the greater the reward holds true here. An investment in Nio is risky due to external factors beyond the company’s control.
Who owns the most Nio stock?
Top 10 Owners of NIO Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Baillie Gifford & Co. | 5.76% | 88,858,365 |
| BlackRock Fund Advisors | 2.60% | 40,093,147 |
| The Vanguard Group, Inc. | 2.40% | 36,994,474 |
| SSgA Funds Management, Inc. | 2.13% | 32,887,731 |
How far can a Nio car go on one charge?
Not the standard 75-kWh one, mind you, or the 100-kWh long range pack. The killer here is a 150-kWh « ultra long range » battery pack that Nio says enables a range « over 1,000 km » (620 miles).
Where is BNGO based?
The company was founded in 2003 and is headquartered in San Diego, California.
Where is BNGO located?
The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
What kind of company is Bionano genomics?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
Who is invested in Bionano genomics?
LC Ventures and Domain Associates are the most recent investors. Bionano Genomics has acquired 2 organizations. Their most recent acquisition was BioDiscovery on Oct 12, 2021 . They acquired BioDiscovery for $100M .
What companies invested BNGO?
Bionano Genomics (NASDAQ:BNGO) Institutional Buying and Selling
| Reporting Date | Hedge Fund | Ownership in Company |
|---|---|---|
| 2/11/2022 | Geode Capital Management LLC | 1.630% |
| 2/11/2022 | Charles Schwab Investment Management Inc. | 0.709% |
| 2/11/2022 | Bank of Montreal Can | 0.082% |
| 2/10/2022 | JPMorgan Chase & Co. | 0.064% |
How many employees does BNGO have?
Compare BNGO With Other Stocks
| Bionano Genomics Annual Number of Employees | |
|---|---|
| 2020 | 147 |
| 2019 | 97 |
| 2018 | 77 |
| 2017 | 65 |
Who are Bionano genomics competitors?
13 Competitors
BioNano Genomics’s competitors are BioDiscovery, Fluxion Biosciences, IRX Therapeutics, Hepregen, Genvault Corporation and more.
How does Bionano genomics make money?
Revenue is produced by either directly selling the data to outsiders or by leveraging it for internal reasons, such as increasing the efficacy of advertising.
Join TheMoney.co community and don’t forget to share this post !
